Premature newborns' need for transfusions declines with ESA use

06/18/2013 | Medscape (free registration)

Treating preterm infants with an erythropoiesis-stimulating agent such as darbepoetin alfa can help decrease the use of red blood cell transfusions, according to a study in the journal Pediatrics. Infants given the drugs in a trial at high-altitude hospitals were given fewer transfusions. Fifty-nine percent of infants administered darbepoetin alfa and 52% of infants given erythropoietin did not receive transfusions, compared with 38% for the placebo group.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA
Senior Compliance Analyst
ACell, Inc.
Columbia, MD
Assistant General Counsel, Regulatory FDA
Cardinal Health
Columbus, OH
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ